Immune checkpoint inhibitors can produce powerful anticancer responses, but immune activation can also cause inflammation in normal tissues. Early recognition and guideline-based management of immune-related adverse events are essential.
Immunotherapy Has Changed Cancer Treatment
Immune checkpoint inhibitors have transformed the treatment of multiple cancers.
Agents targeting pathways such as:
- PD-1
- PD-L1
- CTLA-4
can enhance antitumor immune responses.
But activating the immune system can sometimes produce inflammation in healthy tissues.
These complications are called immune-related adverse events (irAEs).
Which Organs Can Be Affected?
Immune-related inflammation can involve virtually any organ.
Skin
- Rash
- Pruritus
- Vitiligo
Gastrointestinal tract
- Diarrhea
- Colitis
- Abdominal pain
Liver
- Hepatitis
- Elevated liver enzymes
Endocrine organs
- Thyroiditis
- Hypothyroidism
- Hyperthyroidism
- Hypophysitis
- Adrenal insufficiency
Lungs
- Pneumonitis
Kidneys
- Nephritis
Nervous system
- Neuropathies
- Encephalitis
- Other neurologic syndromes
Why Early Recognition Matters
An important feature of irAEs is that they may initially resemble ordinary treatment symptoms or unrelated illnesses.
For example:
Fatigue may be nonspecific—or may reflect endocrine dysfunction.
Cough may represent infection—or pneumonitis.
Diarrhea may be infectious or dietary—or immune-mediated colitis.
Clinical context is therefore essential.
Patients receiving checkpoint inhibitors should have a low threshold for reporting new or persistent symptoms to their oncology team.
What Does Evaluation Involve?
Management depends on the suspected organ system and severity.
Clinicians may need to:
- Investigate alternative causes
- Perform laboratory testing
- Obtain imaging
- Hold immunotherapy temporarily
- Administer corticosteroids
- Use additional immunosuppression when indicated
- Involve specialist teams
Treatment should be guided by established oncology guidelines.
Symptoms That Deserve Prompt Attention
Patients receiving immunotherapy should promptly report:
- New or worsening shortness of breath
- Persistent diarrhea
- Severe abdominal pain
- Jaundice
- Severe weakness
- Confusion
- New neurologic symptoms
- Severe headache
- Vision changes
- Chest pain
- Significant palpitations
- Unexplained fever
Some symptoms may require urgent or emergency evaluation.
Does Every Adverse Event Mean Immunotherapy Must Stop?
No.
Management depends on:
- Organ involved
- Severity
- Response to treatment
- Recurrence
- Immunotherapy class
- Available treatment alternatives
Some patients can resume immunotherapy after appropriate management.
Others may require permanent discontinuation.
This is why an automatic “stop” or “continue” rule is inappropriate.
The Integrative Oncology Perspective
Integrative oncology should complement—not interfere with—appropriate toxicity management.
Patients should tell their oncology team about:
- Supplements
- Herbal medicines
- Intravenous therapies
- Special diets
- Complementary treatments
This is particularly important because some interventions can affect:
- Bleeding
- Liver function
- Renal function
- Immune activity
- Drug metabolism
Bottom Line
Immune checkpoint inhibitors can produce durable anticancer responses, but immune activation can also affect healthy organs.
Early recognition, appropriate investigation and guideline-based management are essential.
The safest integrative approach is one that recognizes complications early and works alongside evidence-based oncology rather than delaying or replacing appropriate treatment.
Category: Immunotherapy
Tags: Immunotherapy, immune-related adverse events, checkpoint inhibitors, cancer treatment side effects, oncology, pembrolizumab, nivolumab
Focus keyword: immunotherapy side effects
Leave a Reply